Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D P Carbone

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Seminars in Oncology|August 1, 1997
The biology of lung cancerD P Carbone
Oncology (Williston Park, N.Y.)|November 7, 1999
Molecular modalities in the treatment of lung cancerD P Carbone
Hospital Practice (Office Ed.)|June 15, 1993
Oncogenes and tumor suppressor genesD P Carbone
Cancer Treatment and Research|February 28, 2001
Biological considerations in lung cancerB Almand, D P Carbone
Journal of the National Cancer Institute|October 5, 1994
In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirusD P Carbone, J D Minna
Molecular Medicine Today|April 1, 1997
p53 as a target for anti-cancer immunotherapyH L Chen, D P Carbone
Current Opinion in Oncology|June 10, 1998
Immunotherapy of head and neck cancerJ R Resser, D P Carbone
BMJ (Clinical Research Ed.)|October 7, 1995
Chemotherapy for non-small cell lung cancerD P Carbone, J D Minna
Hematology/Oncology Clinics of North America|August 1, 1996
Immunologic dysfunction in cancerD Y Kavanaugh, D P Carbone
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Increased dose-intensity in small-cell lung cancer: a failed strategy?D H Johnson, D P Carbone
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Seminars in Oncology|August 1, 1997
The biology of lung cancerD P Carbone
Oncology (Williston Park, N.Y.)|November 7, 1999
Molecular modalities in the treatment of lung cancerD P Carbone
Hospital Practice (Office Ed.)|June 15, 1993
Oncogenes and tumor suppressor genesD P Carbone
Cancer Treatment and Research|February 28, 2001
Biological considerations in lung cancerB Almand, D P Carbone
Journal of the National Cancer Institute|October 5, 1994
In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirusD P Carbone, J D Minna
Molecular Medicine Today|April 1, 1997
p53 as a target for anti-cancer immunotherapyH L Chen, D P Carbone
Current Opinion in Oncology|June 10, 1998
Immunotherapy of head and neck cancerJ R Resser, D P Carbone
BMJ (Clinical Research Ed.)|October 7, 1995
Chemotherapy for non-small cell lung cancerD P Carbone, J D Minna
Hematology/Oncology Clinics of North America|August 1, 1996
Immunologic dysfunction in cancerD Y Kavanaugh, D P Carbone
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Increased dose-intensity in small-cell lung cancer: a failed strategy?D H Johnson, D P Carbone
Pageof 10